Treating multiple myeloma in the era of new drugs: What is the right choice?

被引：0
|
作者：
Perego, Gianluca [1 ]
Paris, Laura [2 ]
Nozza, Silvia [1 ]
Stefanoni, Paola [2 ]
Franzin, Michela [1 ]
机构：
[1] ASST Papa Giovanni XXIII, Pharm Unit, Bergamo, Italy
[2] ASST Papa Giovanni XXIII, Dept Oncol & Hematol, Bergamo, Italy
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2023年 / 29卷 / 05期
关键词：
New drugs; newly diagnosed multiple myeloma; relapsed and refractory multiple myeloma; ELIGIBLE PATIENTS; OPEN-LABEL; DARATUMUMAB; DEXAMETHASONE; BORTEZOMIB;
D O I：
10.1177/10781552231176499
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1234 / 1236
页数：3
相关论文
共 50 条
  • [41] Is there a role for new drugs with alkylating properties in multiple myeloma?
    Mateos, Maria-Victoria
    Gonzalez-Calle, Veronica
    LANCET HAEMATOLOGY, 2020, 7 (05): : E357 - E359
  • [42] New drugs in multiple myeloma - role of carfilzomib and pomalidomide
    Jurczyszyn, Artur
    Legiec, Wojciech
    Helbig, Grzegorz
    Hus, Marek
    Kyrcz-Krzemien, Slawomira
    Skotnicki, Aleksander B.
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2014, 18 (01): : 17 - 21
  • [43] New drugs and novel therapeutic principles in multiple myeloma
    San Miguel, J.
    Mateos, M. V.
    Ocio, E.
    EJC SUPPLEMENTS, 2009, 7 (02): : 21 - 21
  • [44] NEW ERA IN MULTIPLE MYELOMA. CONSEQUENCES OF THE ARRIVAL OF NEW AGENTS
    Sobejano Fuertes, E.
    Gonzalez, V
    Higuero, V
    Garcia-Sanz, R.
    Presa, D.
    Azibeiro, R.
    Fonseca, M.
    Rey, B.
    Puig, N.
    Gutierrez, N.
    Leoz, P.
    Labrador, J.
    Aguilera, C.
    Escalante, F.
    Alonso Jose, M.
    Lopez, R.
    Garcia-Mateo, A.
    Garcia de Coca, A.
    Hernandez, R.
    Barez, A.
    Redondo, E.
    Mateos, M., V
    HAEMATOLOGICA, 2019, 104 : 20 - 21
  • [45] THE ROLE OF CHEMOTHERAPY IN THE ERA OF NEW DRUGS: A MONOCENTRIC EXPERIENCE ON ADVANCED PHASE MULTIPLE MYELOMA PATIENTS TREATED WITH CYCLOPHOSPHAMIDE
    Massaro, F.
    Rivolti, E.
    Soci, F.
    Quaresima, M.
    Tognazzi, L.
    Gamberi, B.
    Merli, F.
    HAEMATOLOGICA, 2019, 104 : 71 - 72
  • [46] Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs
    Morabito, Fortunato
    Gentile, Massimo
    Mazzone, Carla
    Bringhen, Sara
    Vigna, Ernesto
    Lucia, Eugenio
    Recchia, Anna G.
    Raimondo, Francesco D.
    Musto, Pellegrino
    Palumbo, Antonio
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 181 - 191
  • [47] Allogeneic transplant for myeloma in the era of new drugs: have the outcomes improved?
    El-Cheikh, Jean
    Crocchiolo, Roberto
    Boher, Jean-Marie
    Fuerst, Sabine
    Stoppa, Anne Marie
    Faucher, Catherine
    Castagna, Luca
    Granata, Angela
    Oudin, Claire
    De Colella, Jean-Marc Schiano
    Coso, Diane
    Bouabdallah, Reda
    Mohty, Mohamad
    Blaise, Didier
    LEUKEMIA & LYMPHOMA, 2012, 53 (08) : 1630 - 1632
  • [48] ANTIHYPERTENSIVE DRUGS OF CHOICE FOR TREATING PREECLAMPSIA
    CONNELLY, JF
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1994, 51 (14): : 1766 - 1767
  • [49] Prognostic Impact of Hyperdiploidy on Multiple Myeloma in the Era of New Agents
    Wang, Yi
    Zhuang, Jing
    An, Gang
    Mao, Xue-Han
    Du, Chenxing
    Liu, Jiahui
    Fan, Huishou
    Deng, Shuhui
    Xu, Yan
    Sui, Weiwei
    Qiu, Lugui
    BLOOD, 2020, 136
  • [50] WHAT ARE THE NEW AGENTS IN THE MANAGEMENT OF PATIENTS WITH MULTIPLE MYELOMA?
    Abonour, Rafat
    LEUKEMIA RESEARCH, 2014, 38 : S14 - S15
12345